NRSN•prnewswire•
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
Summary
Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 8, 2026 by prnewswire